Tomasz Stompór

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 205 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis

Tomasz Stompór, Mieczysław Pasowicz, Władysław Sułowicz et al. · American Journal of Kidney Diseases · 2002 · 164 citations

Inflammation, Metabolic Syndrome, Hemodialysis +13

The pharmacokinetics of pioglitazone in patients with impaired renal function

Klemens Budde, Hans‐Hellmut Neumayer, Lutz Fritsche et al. · British Journal of Clinical Pharmacology · 2003 · 141 citations · Full text